Fig. 2: Increased H3 methylation in drug-tolerant persister cells.
From: Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastoma
a Heatmap of peak areas for H3 peptides in parent (Par) and CMPD1 (25 μM, 14 days) derived drug-tolerant persister (DTP) cells. Data are parent-DTP pairs of 3 biological replicates performed in triplicate. b The sum of H3.1/3.2K27K36 peptides peak area was divided by the sum of H3.3K27K36 peptides peak area within each sample. Data are mean ± SD (n = 3 biological replicates). Multiple unpaired t-test between DTP vs Parent: ** indicates p = 0.0012, p = 0.0096 for RKI1 and FPW1, respectively. c Representative immunoblots of total H3, H3.1/H3.2 and H3.3 variants in parent and CMPD1 (25 μM, 14 days) derived drug-tolerant persister cells. Quantification of n = 3 biological replicates is provided in the Supplementary Fig. 2c. d, e Relative abundance of H3.1/3.2K27K36 peptides in parent and CMPD1 (25 μM, 14 days) derived drug-tolerant persister cells. Data are mean ± SD (n = 3 biological replicates; multiple unpaired t-test). f Representative immunoblots of total and methylated H3 in parent and CMPD1 (25 µM, 14 days) derived drug-tolerant persister cells. Quantification of n = 3 biological replicates is provided in the Supplementary Fig. 2d. g Representative immunoblots of H3K4me1, H3K4me2 and total H3 in parent and CMPD1 (25 µM, 14 days) derived drug-tolerant persister cells. Quantification of n = 2 biological replicates is provided in the Supplementary Fig. 2e. h Representative immunoblots of H3K4me3, H3K9me3, cleaved histone H3 and total H3 in RKI1 and FPW1 cells treated with CMPD1 (25 µM). Average histone levels (n = 3 biological replicates for H3K9me3 in RKI1 cells; n = 4 for all other treatments) are shown below the immunoblots, with individual quantification provided in the Supplementary Fig. 2f. Source data are provided as a Source Data file.
